Farallon Capital Management LLC Raises Position in Amyris, Inc. (NASDAQ:AMRS)

Farallon Capital Management LLC boosted its holdings in Amyris, Inc. (NASDAQ:AMRSGet Rating) by 55.9% in the first quarter, Holdings Channel reports. The institutional investor owned 16,931,427 shares of the biotechnology company’s stock after acquiring an additional 6,071,616 shares during the quarter. Farallon Capital Management LLC owned 0.05% of Amyris worth $73,821,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of AMRS. State of Michigan Retirement System raised its holdings in Amyris by 92.2% during the 1st quarter. State of Michigan Retirement System now owns 4,815,000 shares of the biotechnology company’s stock valued at $20,993,000 after acquiring an additional 2,310,000 shares during the period. Edmond DE Rothschild Holding S.A. lifted its holdings in Amyris by 83.9% during the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 4,563,800 shares of the biotechnology company’s stock worth $19,898,000 after purchasing an additional 2,081,500 shares in the last quarter. Bank of Montreal Can purchased a new stake in Amyris during the 4th quarter worth about $8,443,000. Laurion Capital Management LP purchased a new stake in Amyris during the 4th quarter worth about $6,704,000. Finally, Landscape Capital Management L.L.C. purchased a new stake in Amyris during the 1st quarter worth about $5,036,000. Institutional investors own 43.08% of the company’s stock.

Amyris Stock Performance

NASDAQ:AMRS opened at $3.93 on Tuesday. The business’s 50-day moving average price is $2.56 and its two-hundred day moving average price is $3.06. Amyris, Inc. has a twelve month low of $1.47 and a twelve month high of $15.12. The stock has a market cap of $1.26 billion, a P/E ratio of -2.60 and a beta of 1.36. The company has a quick ratio of 1.13, a current ratio of 1.66 and a debt-to-equity ratio of 1.26.

Amyris (NASDAQ:AMRSGet Rating) last released its quarterly earnings results on Tuesday, August 9th. The biotechnology company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.06). The business had revenue of $65.20 million during the quarter, compared to analysts’ expectations of $81.53 million. During the same quarter in the prior year, the firm posted ($0.16) earnings per share. The firm’s quarterly revenue was up 24.7% on a year-over-year basis. As a group, equities analysts predict that Amyris, Inc. will post -1.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

AMRS has been the topic of a number of recent research reports. Roth Capital cut Amyris from a “buy” rating to a “neutral” rating in a report on Wednesday, August 10th. JPMorgan Chase & Co. initiated coverage on Amyris in a report on Friday, June 24th. They set a “neutral” rating on the stock. Finally, Piper Sandler initiated coverage on Amyris in a report on Wednesday, May 25th. They set a “neutral” rating and a $2.50 price objective on the stock.

Insider Buying and Selling at Amyris

In other Amyris news, insider Nicole Kelsey sold 94,033 shares of the firm’s stock in a transaction dated Thursday, June 30th. The stock was sold at an average price of $1.80, for a total value of $169,259.40. Following the sale, the insider now owns 63,333 shares of the company’s stock, valued at approximately $113,999.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, insider Nicole Kelsey sold 94,033 shares of the stock in a transaction dated Thursday, June 30th. The stock was sold at an average price of $1.80, for a total transaction of $169,259.40. Following the transaction, the insider now directly owns 63,333 shares in the company, valued at approximately $113,999.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John Melo sold 55,576 shares of the stock in a transaction dated Wednesday, July 6th. The shares were sold at an average price of $2.12, for a total value of $117,821.12. Following the transaction, the chief executive officer now owns 492,701 shares in the company, valued at $1,044,526.12. The disclosure for this sale can be found here. Insiders own 33.80% of the company’s stock.

Amyris Profile

(Get Rating)

Amyris, Inc, a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets.

Featured Stories

Want to see what other hedge funds are holding AMRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amyris, Inc. (NASDAQ:AMRSGet Rating).

Institutional Ownership by Quarter for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.